Evidence map›Paper›PMID 42234375›Full record

ArticleMolecular biotechnology2026

MicroRNA-181a-5p promotes papillary thyroid carcinoma progress via the PTEN/AKT pathway.

Wenyu Zhao, Yiting Guo, Liang He, Junhong Li, Zhenglun Qiu, Haojie Chen, Leilei Li, Hua Wang, Yunlong Wang, Yanfang Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenyu ZhaoDepartment of Endocrinology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471009, Henan Province, People's Republic of China.
Yiting GuoDepartment of Endocrinology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471009, Henan Province, People's Republic of China.
Liang HeDepartment of Thyroid and Breast Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471009, Henan Province, China.
Junhong LiDepartment of Pathology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471009, Henan Province, China.
Zhenglun QiuDepartment of Thyroid and Breast Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471009, Henan Province, China.
Haojie ChenDepartment of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471009, Henan Province, China.
Leilei LiDepartment of Thyroid and Breast Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471009, Henan Province, China.
Hua WangDepartment of Ultrasound, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471009, Henan Province, China.
Yunlong WangZhongyuan Scholars Workstation of Henan, Luoyang, 471000, Henan Province, China.
Yanfang ZhangDepartment of Endocrinology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471009, Henan Province, People's Republic of China. yanfangz@zzu.edu.cn.ORCID http://orcid.org/0009-0001-8078-0785

Funding

Graduate research innovation program of Xinxiang Medical College 0 RMBGraduate research innovation program of Xinxiang Medical College 300Henan Provincial Science and Technology Research Project 000 RMBHenan Provincial Science and Technology Research Project 200Innovative leading talents of science and technology project of Health Commission of Henan Province 000 RMBInnovative leading talents of science and technology project of Health Commission of Henan Province 400Medical key project of Luoyang City 000 RMBMedical key project of Luoyang City 300
6 · The paper itself

Abstract

The objective of this investigation was to determine the expression profile and latent mechanism of microRNA-181a-5p (miR-181a-5p) in the genesis and progression of papillary thyroid cancer (PTC). MiR-181a-5p was discovered to be upregulated in PTC tissues and cells in this study, as confirmed by RT‒qPCR and The Cancer Genome Atlas database. Notably, in PTC patients, the miR-181a-5p level was linked to tumor size and thyroid capsule invasion. A series of experiments demonstrated that miR-181a-5p upregulation in PTC cells notably enhanced proliferation, motility, and invasion, whereas suppressing miR-181a-5p hindered these functions. Western blotting revealed that miR-181a-5p suppressed PTEN expression, boosting the activation of phosphorylated AKT (P-AKT). According to predictive bioinformatics research and luciferase reporter gene tests, miR-181a-5p may target a specific binding site on the PTEN 3'UTR. To sum up, this study indicated that miR-181a-5p promoted PTC progression through the PTEN/Akt pathway. This investigation reveals a potential mechanism for PTC progression and provides a foundation for clinical therapies.

Indexed as

MicroRNAsProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseThyroid Cancer, PapillaryThyroid Neoplasms3' Untranslated RegionsCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansSignal Transduction3' Untranslated RegionsMicroRNAsMIrn181 microRNA, humanProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanBiomarkerMiR-181a-5pPapillary thyroid cancerPTENPTEN/Akt pathway

Identifiers

PMID42234375
PMCPMC13558409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.